US20240341254
2024-10-17
Human necessities
A01H6/28
Cannabis plants are known to produce a variety of cannabinoids, including tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV). These varin molecules have distinct pharmacological properties and target different molecular pathways. They show promise in treating conditions such as epilepsy, obesity-related issues, anxiety disorders, and chronic pain, making them valuable for both medical and recreational use.
Varins differ from traditional cannabinoids by having shorter alkyl side chains. THCV and CBDV are homologues of THC and CBD, respectively, but exhibit unique effects. For instance, THCV has been highlighted for its potential as an appetite suppressant and anticonvulsant, while CBDV is noted for its anti-epileptic properties. These unique profiles present new therapeutic avenues for patients with various health concerns.
Despite their potential, the prevalence of THCV and CBDV in naturally occurring cannabis is low, limiting research and product development. The ability to cultivate cannabis strains with elevated levels of these cannabinoids could lead to new product categories that cater to specific health needs, thus enhancing market opportunities in both medical and recreational sectors.
The invention introduces novel cannabis plants that possess high concentrations of THCV and/or CBDV, ranging from 5% to 25%. This includes seeds and plant parts that can be cultivated to produce these high-varin varieties. Methods such as backcrossing or genetic transformation may be employed to enhance desired traits in these cannabis plants.
Various products can be derived from these high-varin cannabis plants, including kief, hashish, edibles, oils, and tinctures. The development of these products opens up new avenues for therapeutic applications and consumer enjoyment. Additionally, the cultivation of F1 hybrid seeds from these plants can further diversify the types of cannabis products available on the market.